Curasight AS (CURAS)

Currency in DKK
11.80
+0.50(+4.42%)
Real-time Data·
CURAS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.5012.00
52 wk Range
1.8013.95
Key Statistics
Bid/Ask
11.70 / 11.80
Prev. Close
11.3
Open
11.65
Day's Range
11.5-12
52 wk Range
1.8-13.95
Volume
97.08K
Average Volume (3m)
108.67K
1-Year Change
24.2105%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CURAS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Curasight AS News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Curasight AS Company Profile

Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. It develops uTREAT therapeutic solutions, that are in Phase IIb clinical trials to treat glioblastoma, non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. The company is also developing uTRACE diagnostic solutions, which have completed Phase II clinical trial for the treatment of glioblastoma, prostate cancer, neuroendocrine neoplasms, head and neck cancer, breast cancer, and urinary bladder cancer; and is in Phase II clinical trials to treat non-small cell lung cancer. Curasight A/S was incorporated in 2013 and is based in Copenhagen, Denmark.

Compare CURAS to Peers and Sector

Metrics to compare
CURAS
Peers
Sector
Relationship
P/E Ratio
−11.2x−3.2x−0.6x
PEG Ratio
−0.46−0.130.00
Price/Book
31.0x1.5x2.6x
Price / LTM Sales
-9.8x3.4x
Upside (Analyst Target)
−29.2%211.8%39.6%
Fair Value Upside
Unlock21.6%5.2%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 27, 2025
EPS / Forecast
-0.28 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CURAS Income Statement

FAQ

What Stock Exchange Does Curasight AS Trade On?

Curasight AS is listed and trades on the Spotlight Stock Market stock exchange.

What Is the Stock Symbol for Curasight AS?

The stock symbol for Curasight AS is "CURAS."

What Is the Curasight AS Market Cap?

As of today, Curasight AS market cap is 541.53M.

What Is Curasight AS's Earnings Per Share (TTM)?

The Curasight AS EPS (TTM) is -1.20.

When Is the Next Curasight AS Earnings Date?

Curasight AS will release its next earnings report on 25 Feb 2026.

From a Technical Analysis Perspective, Is CURAS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Curasight AS Stock Split?

Curasight AS has split 0 times.

How Many Employees Does Curasight AS Have?

Curasight AS has 4 employees.

What is the current trading status of Curasight AS (CURAS)?

As of 19 Jan 2026, Curasight AS (CURAS) is trading at a price of 11.80, with a previous close of 11.30. The stock has fluctuated within a day range of 11.50 to 12.00, while its 52-week range spans from 1.80 to 13.95.

What Is Curasight AS (CURAS) Price Target According to Analysts?

The average 12-month price target for Curasight AS is DKK8, with a high estimate of DKK8 and a low estimate of DKK8. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an -32.20% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.